X
<

Who's Watching Alexion Now?

PART:
1 2 3 4
Who's Watching Alexion Now? PART 1 OF 4

Alexion on the Street: Analyst Recommendations in October

Recent approval

In August 2017, the EC (European Commission) approved the label expansion of Alexion Pharmaceuticals’ (ALXN) Soliris to include the use of the drug for the treatment of refractory gMG (generalized myasthenia gravis) in adults who are anti-acetylcholine receptor antibody positive.

The EC approval for label expansion was based on the results of the phase-3 Regain trial (or MG-301) and its long-term open-label extension trial (or MG-302).

Alexion on the Street: Analyst Recommendations in October

Interested in ALXN? Don't miss the next report.

Receive e-mail alerts for new research on ALXN

Success! You are now receiving e-mail alerts for new research. A temporary password for your new Market Realist account has been sent to your e-mail address.

Success! has been added to your Ticker Alerts.

Success! has been added to your Ticker Alerts. Subscriptions can be managed in your user profile.

Analyst ratings

Of the 20 analysts tracking ALXN in October 2017, 85% recommended some form of “buy,” while three analysts recommended a “hold.” None recommended a “sell” or “strong sell.”

On October 2, 2017, Alexion had consensus 12-month target price of $163.45, which implies a ~16.5% return on investment over the next 12 months. Notably, the SPDR S&P 500 ETF (SPY) invests ~0.14% of its total portfolio in ALXN.

Competitor ratings

Notably, 23 analysts were tracking BioMarin Pharmaceuticals (BMRN) in October 2017. Around 78.2% recommended some form of a “buy” rating, while five suggested a “hold,” and none suggested any form of “sell” rating.

On October 2, 2017, BioMarin Pharmaceuticals had 12-month consensus target price of $111.57, which implies a ~19.9% return over the next 12 months.

Of the 27 analysts tracking Vertex Pharmaceuticals (VRTX) in October 2017, 81.4% of the analysts recommended some form of a “buy” rating. Five analysts covering VRTX suggested a “hold, ” and none of them suggested any form of a “sell” rating.

On October 2, 2017, Vertex Pharmaceuticals had consensus 12-month target price of $179.08, which implies a ~17.8% return over the next 12 months.

Among the ten analysts tracking Exelixis (EXEL) in October 2017, ~60% recommended some form of “buy.” Four recommended a “hold,” while none recommended any form of “sell.”

On October 2, 2017, Exelixis had a consensus 12-month target price of ~$29.57, which implies a ~22.0% return over the next 12 months.

X

Please select a profession that best describes you: